Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial-Reference-Cited by-同舟云学术

Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial

Published:2019-10-31 Issue:3 Volume:22 Page:557-559
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Ramalho Sergio H.R.¹²,Claggett Brian L.¹,Sweitzer Nancy K.³,Fang James C.⁴,Shah Sanjiv J.⁵,Anand Inder S.⁶,Pitt Bertram⁷,Lewis Eldrin F.¹,Pfeffer Marc A.¹,Solomon Scott D.¹,Shah Amil M.¹

Affiliation:

1. Division of Cardiovascular MedicineBrigham and Women's Hospital Boston MA USA

2. Health Sciences and Technologies ProgramUniversity of Brasilia Brasilia Brazil

3. University of Arizona Tucson AZ USA

4. University of Utah Salt Lake City UT USA

5. Northwestern University Chicago IL USA

6. University of Minnesota Minneapolis MN USA

7. University of Michigan Ann Arbor MI USA

Funder

Department of Health and Human Services

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1593

Reference11 articles.

1. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology

2. Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction

3. Echo-Doppler Evaluation of Left Ventricular Impairment in Chronic Cor Pulmonale

4. Percent Emphysema, Airflow Obstruction, and Impaired Left Ventricular Filling

5. Spironolactone for Heart Failure with Preserved Ejection Fraction

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Obstructive Pulmonary Disease in Heart Failure: Challenges in Diagnosis and Treatment for HFpEF and HFrEF;Current Heart Failure Reports;2024-03-28

2. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER;European Journal of Heart Failure;2023-09

3. Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT;Journal of Cardiac Failure;2022-09

4. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF;Journal of the American Heart Association;2021-12-07

5. Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial;Cardiovascular Drugs and Therapy;2021-04-01